Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The price of Abbvie Inc (NYSE: ABBV) closed at $230.84 in the last session, up 0.37% from day before closing price of $229.98. In other words, the price has increased by $0.37 from its previous closing price. On the day, 3.36 million shares were traded. ABBV stock price reached its highest trading level at $232.015 during the session, while it also had its lowest trading level at $229.74.
Ratios:
We take a closer look at ABBV’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 71.94 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 20.73. For the most recent quarter (mrq), Quick Ratio is recorded 0.60 and its Current Ratio is at 0.72.
On November 13, 2025, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $280.
DZ Bank Downgraded its Buy to Hold on November 04, 2025, while the target price for the stock was maintained at $237.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 22 ’25 when Richard A. Gonzalez bought 62,755 shares for $210.84 per share.
Richard A. Gonzalez bought 90,000 shares of ABBV for $18,993,948 on Aug 21 ’25. On Aug 12 ’25, another insider, SALEKI-GERHARDT AZITA, who serves as the EVP, CHIEF OPERATIONS OFFICER of the company, sold 42,370 shares for $198.42 each. As a result, the insider received 8,407,055 and left with 177,292 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABBV now has a Market Capitalization of 407983063040 and an Enterprise Value of 471204069376. As of this moment, Abbvie’s Price-to-Earnings (P/E) ratio for their current fiscal year is 174.18, and their Forward P/E ratio for the next fiscal year is 16.15. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.00. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.84. Its current Enterprise Value per Revenue stands at 7.9 whereas that against EBITDA is 15.963.
Stock Price History:
The Beta on a monthly basis for ABBV is 0.35, which has changed by 0.29420376 over the last 52 weeks, in comparison to a change of 0.17823458 over the same period for the S&P500. Over the past 52 weeks, ABBV has reached a high of $244.81, while it has fallen to a 52-week low of $164.39. The 50-Day Moving Average of the stock is 1.80%, while the 200-Day Moving Average is calculated to be 12.11%.
Shares Statistics:
According to the various share statistics, ABBV traded on average about 5.94M shares per day over the past 3-months and 5859700 shares per day over the past 10 days. A total of 1.77B shares are outstanding, with a floating share count of 1.77B. Insiders hold about 0.09% of the company’s shares, while institutions hold 74.67% stake in the company. Shares short for ABBV as of 1765756800 were 18075534 with a Short Ratio of 3.04, compared to 1763078400 on 18724102. Therefore, it implies a Short% of Shares Outstanding of 18075534 and a Short% of Float of 1.0199999.
Dividends & Splits
The forward annual dividend rate for ABBV is 6.56, which was 6.56 in the trailing 12 months. Against a Trailing Annual Dividend Yield of 0.02852422. The stock’s 5-year Average Dividend Yield is 3.75.
Earnings Estimates
As of right now, 18.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $3.11, with high estimates of $3.41 and low estimates of $2.92.
Analysts are recommending an EPS of between $10.8 and $10.5 for the fiscal current year, implying an average EPS of $10.64. EPS for the following year is $14.25, with 28.0 analysts recommending between $15.43 and $13.26.
Revenue Estimates
According to 17 analysts,. The current quarter’s revenue is expected to be $16.39B. It ranges from a high estimate of $17.01B to a low estimate of $16.23B. As of. The current estimate, Abbvie Inc’s year-ago sales were $15.1BFor the next quarter, 17 analysts are estimating revenue of $14.74B. There is a high estimate of $15.2B for the next quarter, whereas the lowest estimate is $14.45B.
A total of 27 analysts have provided revenue estimates for ABBV’s current fiscal year. The highest revenue estimate was $61.55B, while the lowest revenue estimate was $60.5B, resulting in an average revenue estimate of $60.93B. In the same quarter a year ago, actual revenue was $56.33BBased on 27 analysts’ estimates, the company’s revenue will be $66.68B in the next fiscal year. The high estimate is $68.7B and the low estimate is $65.31B.
